drugset / Trial / NCT04570839
COM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors.
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a phase 1/2 open label sequential dose escalation and cohort expansion study evaluating the safety, tolerability and preliminary antitumor activity of COM701 in combination with BMS-986207 and nivolumab in patients with advanced solid tumors.
Timeline
- Start
- 2020-08-31
- Primary completion
- 2024-05-15
- Completion
- 2024-05-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | COM701 | Monoclonal antibody | — | Intravenous |
| Background | Nivolumab | Monoclonal antibody | — | Intravenous |
| Background | RENVISTOBART | Monoclonal antibody | — | Intravenous |